{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:40:18Z","timestamp":1787578818212,"version":"build-2736575974"},"reference-count":61,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: Schizophrenia is a chronic disorder requiring long-term pharmacological treatment. Many patients experience inadequate response and adverse effects, often leading to poor adherence and need for antipsychotic switch or polypharmacotherapy. In this context, brexpiprazole, an atypical antipsychotic with favorable tolerability profile, may offer clinical benefits following previous treatment failure or intolerance. However, real-world evidence after treatment switch remains limited. Methods: This retrospective, observational study included 50 outpatients with schizophrenia switched to brexpiprazole (2\u20134 mg\/day) via cross-titration and evaluated over 12 weeks. Primary outcomes were changes in Patient Life Engagement, assessed through a 14-item subset of the Positive and Negative Syndrome Scale (PANSS), along with response\/remission rates. Secondary outcomes included changes in subjective well-being, quality of life, sexual functioning (based on Subjective Well-being under Neuroleptics\u2014Short Form [SWN-S], WHO-5 Well-Being Index [WHO-5], and Arizona Sexual Experience Scale [ASEX] scores, respectively), metabolic parameters, and prolactin levels. Results: Life engagement improved significantly (p &lt; 0.001) across all domains, and clinical response was achieved in 40% of patients. Significant improvements were observed in SWN-S and WHO-5 scores (both p &lt; 0.001). Weight and BMI significantly decreased (\u20132.64 kg, p = 0.013, and \u20130.91 kg\/m2, p = 0.006, respectively). Numerical non-significant reductions were found in ASEX (p = 0.067) and prolactin levels (\u201330.7 ng\/mL, p = 0.077). Overall, treatment was well-tolerated. Conclusions: Switching to brexpiprazole was associated with improvements in psychopathological, functional, and physical health domains. These findings support its potential role in real-world, personalized therapeutic strategies for patients with schizophrenia following suboptimal outcomes with prior antipsychotic treatments.<\/jats:p>","DOI":"10.3390\/jpm15110502","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T05:20:44Z","timestamp":1761196844000},"page":"502","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient Life Engagement and Metabolic Profile Improve After Switching from First-\/Second-Generation Antipsychotics to Brexpiprazole: A Real-World Study in Patients with Schizophrenia"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7457-0426","authenticated-orcid":false,"given":"Marco","family":"Di Nicola","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Department of Psychiatry, Fondazione Policlinico Universitario \u2018Agostino Gemelli\u2019 IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7597-6916","authenticated-orcid":false,"given":"Maria","family":"Pepe","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fondazione Policlinico Universitario \u2018Agostino Gemelli\u2019 IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7642-7348","authenticated-orcid":false,"given":"Miriam","family":"Milintenda","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8868-4757","authenticated-orcid":false,"given":"Marco","family":"Massetti","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-6060","authenticated-orcid":false,"given":"Lorenzo","family":"Moccia","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fondazione Policlinico Universitario \u2018Agostino Gemelli\u2019 IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3548-0302","authenticated-orcid":false,"given":"Isabella","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Mental Health Department, ASL Roma 1, 00193 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9767-8752","authenticated-orcid":false,"given":"Gabriele","family":"Sani","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Department of Psychiatry, Fondazione Policlinico Universitario \u2018Agostino Gemelli\u2019 IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia\u2014Data, with critical appraisal, from the Global Burden of Disease (GBD) 2019","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"ref_2","unstructured":"World Health Organization Schizophrenia 2022. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1017\/S2045796023000045","article-title":"Schizophrenia as a risk factor for cardiovascular and metabolic health outcomes: A comparative risk assessment","volume":"32","author":"Ali","year":"2023","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpsychires.2020.07.038","article-title":"The metabolic effects of antipsychotics in the early stage of treatment in first-episode patients with schizophrenia: A real-world study in a naturalistic setting","volume":"129","author":"Cao","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: A systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jamapsychiatry.2021.0015","article-title":"Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia: A Systematic Review and Meta-analysis","volume":"78","author":"Hagi","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/2045125318781475","article-title":"The acute efficacy of antipsychotics in schizophrenia: A review of recent meta-analyses","volume":"8","author":"Haddad","year":"2018","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Moccia, L., Bardi, F., Anesini, M.B., Barbonetti, S., Kotzalidis, G.D., Rossi, S., Caso, R., Grisoni, F., Mandracchia, G., and Margoni, S. (2025). Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials. Biomedicines, 13.","DOI":"10.3390\/biomedicines13030540"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"El Abdellati, K., De Picker, L., and Morrens, M. (2020). Antipsychotic Treatment Failure: A Systematic Review on Risk Factors and Interventions for Treatment Adherence in Psychosis. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.531763"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.schres.2008.02.021","article-title":"Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia","volume":"102","author":"Kinon","year":"2008","journal-title":"Schizophr. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40261-021-01000-1","article-title":"Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects","volume":"41","author":"Rognoni","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13643-021-01760-z","article-title":"Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: Protocol for a systematic review and network meta-analysis of randomized controlled trials","volume":"10","author":"Kapfhammer","year":"2021","journal-title":"Syst. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"21m14272","DOI":"10.4088\/JCP.21m14272","article-title":"Reasons for Antipsychotic Treatment Switch: A Systematic Retrospective Review of Prescription Records and Prescriber Notes","volume":"83","author":"Guinart","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1017\/S1092852918001086","article-title":"Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: Comparison of clinicians\u2019 choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study","volume":"24","author":"Correll","year":"2019","journal-title":"CNS Spectr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3371\/CSRP.MCCI.010316","article-title":"Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator","volume":"9","author":"McEvoy","year":"2016","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40263-020-00718-4","article-title":"Comparative Tolerability of Dopamine D2\/3 Receptor Partial Agonists for Schizophrenia","volume":"34","author":"Keks","year":"2020","journal-title":"CNS Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: A systematic review and network meta-analysis","volume":"399","author":"Chalkou","year":"2022","journal-title":"Lancet"},{"key":"ref_19","unstructured":"European Medicines Agency (EMA) Rxulti (brexpiprazole)\u2014An overview of Rxulti and why it is authorised in the EU. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/rxulti-epar-medicine-overview_en.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Chiappini, S., Cavallotto, C., Mosca, A., Di Carlo, F., Piro, T., Giovannetti, G., Pasino, A., Vicinelli, M., Lorenzini, C., and Di Paolo, M. (2024). Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study. Pharmaceuticals, 17.","DOI":"10.3390\/ph17040535"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.64719\/pb.4399","article-title":"Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice","volume":"51","author":"Edinoff","year":"2021","journal-title":"Psychopharmacol. Bull."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1007\/s00213-021-05983-9","article-title":"The prevalence and clinical correlates of metabolic syndrome and cardiometabolic alterations in 430 drug-naive patients in their first episode of schizophrenia","volume":"238","author":"Lang","year":"2021","journal-title":"Psychopharmacology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105344","DOI":"10.1016\/j.psyneuen.2021.105344","article-title":"Differences in patterns of metabolic abnormality and metabolic syndrome between early-onset and adult-onset first-episode drug-naive schizophrenia patients","volume":"132","author":"Lang","year":"2021","journal-title":"Psychoneuroendocrinology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.2147\/DDDT.S240859","article-title":"Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist\u2019s Perspective","volume":"14","author":"Watanabe","year":"2020","journal-title":"Drug Des. Devel Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/03007995.2024.2440059","article-title":"Effects of brexpiprazole on patient life engagement in schizophrenia: Post hoc analysis of Positive and Negative Syndrome Scale data","volume":"41","author":"Ismail","year":"2025","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s41687-021-00380-4","article-title":"Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: Post hoc analysis of patient-reported outcomes from clinical trial exit interviews","volume":"5","author":"Weiss","year":"2021","journal-title":"J. Patient Rep. Outcomes"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7943","DOI":"10.1017\/S0033291723002106","article-title":"Life engagement in people living with schizophrenia: Predictors and correlates of patient life engagement in a large sample of people living in the community","volume":"53","author":"Vita","year":"2023","journal-title":"Psychol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association. [5th ed.].","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"ref_30","first-page":"5","article-title":"Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary","volume":"64","author":"Kane","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.schres.2024.10.008","article-title":"Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale","volume":"274","author":"Ismail","year":"2024","journal-title":"Schizophr. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","article-title":"Defining \u2018response\u2019 in antipsychotic drug trials: Recommendations for the use of scale-derived cutoffs","volume":"32","author":"Leucht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: Proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/acps.12849","article-title":"Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia","volume":"137","author":"Lin","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_36","first-page":"18","article-title":"Italian validation of Arizona Sexual Experience Scale (ASEX) on patients suffering from psychotic spectrum disorders","volume":"57","author":"Jannini","year":"2022","journal-title":"Riv. Psichiatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/009262300278623","article-title":"The Arizona Sexual Experience Scale (ASEX): Reliability and validity","volume":"26","author":"McGahuey","year":"2000","journal-title":"J. Sex. Marital. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0920-9964(01)00319-X","article-title":"Improvement of schizophrenic patients\u2019 subjective well-being under atypical antipsychotic drugs","volume":"57","author":"Naber","year":"2001","journal-title":"Schizophr. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1034\/j.1399-6576.1999.430906.x","article-title":"Health-Related Quality of Life Measurements in the Assessment of Pain Clinic Results","volume":"43","author":"Bech","year":"1999","journal-title":"Acta Anaesthesiol. Scand."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000376585","article-title":"The WHO-5 Well-Being Index: A systematic review of the literature","volume":"84","author":"Topp","year":"2015","journal-title":"Psychother. Psychosom."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"MS19053BR2C","DOI":"10.4088\/JCP.MS19053BR2C","article-title":"Using Patient-Centered Assessment in Schizophrenia Care: Defining Recovery and Discussing Concerns and Preferences","volume":"81","author":"Correll","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2147\/NDT.S199048","article-title":"The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia","volume":"15","author":"Pietrini","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Di Nicola, M., Pepe, M., D\u2019andrea, G., Marcelli, I., Pettorruso, M., Andriola, I., Barlati, S., Carminati, M., Cattaneo, C.I., and Clerici, M. (2025). Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience). J. Pers. Med., 15.","DOI":"10.3390\/jpm15040161"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11920-021-01298-w","article-title":"New Antipsychotic Medications in the Last Decade","volume":"23","author":"Pahwa","year":"2021","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"114997","DOI":"10.1016\/j.psychres.2022.114997","article-title":"Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies","volume":"320","author":"Storosum","year":"2023","journal-title":"Psychiatry Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jad.2024.02.038","article-title":"Sex differences in effectiveness and adverse effects of mood stabilizers and antipsychotics: A systematic review","volume":"352","author":"Ercis","year":"2024","journal-title":"J. Affect. Disord."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"114030","DOI":"10.1016\/j.psychres.2021.114030","article-title":"Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil","volume":"302","author":"Kelly","year":"2021","journal-title":"Psychiatry Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/schbul\/sbab078","article-title":"Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance","volume":"47","author":"Neumeier","year":"2021","journal-title":"Schizophr. Bull."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Gorwood, P., Yildirim, M., Madera-McDonough, J., Fagiolini, A., Arango, C., Correll, C.U., Arc\u00e0, E., Barlassina, A., Selveindran, S., and Sahota, N. (2025). Assessment of functional recovery in patients with schizophrenia, with a focus on early-phase disease: Results from a Delphi consensus and narrative review. BMC Psychiatry, 25.","DOI":"10.1186\/s12888-025-06725-3"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/JCP.0000000000000539","article-title":"How Hyperprolactinemia Affects Sexual Function in Patients Under Antipsychotic Treatment","volume":"36","author":"Arranz","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2021.08.013","article-title":"Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis","volume":"237","author":"Zhu","year":"2021","journal-title":"Schizophr. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/JCP.0000000000000979","article-title":"Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia","volume":"39","author":"Ivkovic","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_53","first-page":"30","article-title":"Brexpiprazole as a New Serotonin-Dopamine Receptor Modulator: Considering the Clinical Relevance for Metabolic Parameters and Prolactin Levels","volume":"16","author":"Nakamura","year":"2019","journal-title":"Innov. Clin. Neurosci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00213-020-05727-1","article-title":"Prevalence of obesity and clinical and metabolic correlates in first-episode schizophrenia relative to healthy controls","volume":"238","author":"Tian","year":"2021","journal-title":"Psychopharmacology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.2174\/1381612827666210804110139","article-title":"Metabolomic Connections between Schizophrenia, Antipsychotic Drugs and Metabolic Syndrome: A Variety of Players","volume":"27","author":"Molina","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/ijnp\/pyab047","article-title":"The Etiology of Metabolic Disturbances in Schizophrenia: Drugs, Genes, and Environment","volume":"24","author":"Reynolds","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"113101","DOI":"10.1016\/j.bbr.2020.113101","article-title":"Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia","volume":"402","author":"Prestwood","year":"2021","journal-title":"Behav. Brain Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40265-021-01556-4","article-title":"Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations","volume":"81","author":"Tiihonen","year":"2021","journal-title":"Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Vasiliu, O. (2022). Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?. Front. Psychiatry, 13.","DOI":"10.3389\/fpsyt.2022.1069432"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S1091","DOI":"10.1192\/j.eurpsy.2023.2317","article-title":"Brexpiprazole augmentation in a clozapine-resistant young schizophrenic patient: A successful case report","volume":"66","author":"Martiadis","year":"2023","journal-title":"Eur. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"103121","DOI":"10.1016\/j.ajp.2022.103121","article-title":"A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy","volume":"72","author":"Orsolini","year":"2022","journal-title":"Asian J. Psychiatr."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/11\/502\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T05:46:01Z","timestamp":1761198361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/11\/502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":61,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jpm15110502"],"URL":"https:\/\/doi.org\/10.3390\/jpm15110502","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]}}}